Almac's diagnostics business unit today announced that it has received a Clinical Laboratory Permit from the New York State Department of Health
Almac’s diagnostics business unit today announced that it has received a Clinical Laboratory Permit from the New York State Department of Health, allowing them to receive patient samples for clinical testing from New York.
Designed to ensure high quality, reliable and accurate clinical laboratory services, the New York State Clinical Laboratory Permit is known for its stringent requirements for laboratory test approval and is recognised as one of the most difficult to obtain.
In addition, Almac have also successfully retained their CAP and CLIA accreditation following an inspection by the College of American Pathologists (CAP). CAP has led as the gold standard in laboratory accreditation for more than 50 years and the stringent inspection program is designed to specifically ensure the highest standard of care for all laboratory patients.
Almac is focused on personalised medicine, providing biomarker services to the Pharmaceutical and Biotech industry. Services range from early phase trial enrichment to full companion diagnostic development with a focus on multiplex signatures. The recent accreditation will now allow Almac to receive patient samples from New York for clinical testing and trial management.
“The growing importance of biomarkers in personalised medicine means that our clinical testing laboratories need to meet the highest standards of quality and safety” said Richard Kennedy, Clinical Laboratory Director at Almac, “the successful receipt of the Clinical Laboratory Evaluation Program (CLEP) permit together with the recent renewal of our CAP accreditation demonstrates that we meet these standards and provides confidence to our clients.”
Including Women of Childbearing Age in Clinical Research
March 26th 2024In recognition of International Women's Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and Marie Teil, Global Head of UCB’s Women of Childbearing Age Program. They speak about the specific challenges women with chronic illnesses face when accessing appropriate treatment and participating in clinical trials, UCB's Women of Childbearing Age Program and it’s most successful strategies, and much more.
Improving Engagement While Maintaining Data Integrity & Validity
March 19th 2024In recognition of Women's Health Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and uMotif's Chief Product Officer, Julia Lakeland, discuss new technologies improving patient engagement and reducing the emotional and logistical burdens of participation, ethical considerations that should be addressed when implementing those technologies, while ensuring patient privacy, and much more.
Looking Forward in the Feasibility/AI Space
May 6th 2024In the fourth and final part of this video interview with ACT editor Andy Studna, Rohit Nambisan, CEO & founder of Lokavant looks into the future of feasibility studies, the integration of AI, and how they are driving more personalized approaches.